Baker Biotech Capital (gp), Llc - Net Worth and Insider Trading

Baker Biotech Capital (gp), Llc Net Worth

The estimated net worth of Baker Biotech Capital (gp), Llc is at least $1.4 Billion dollars as of 2024-09-20. Baker Biotech Capital (gp), Llc is the Director, 10% Owner of Seagen Inc and owns about 4,626,213 shares of Seagen Inc (SGEN) stock worth over $1.1 Billion. Baker Biotech Capital (gp), Llc is the Director, 10% Owner of Incyte Corp and owns about 2,933,021 shares of Incyte Corp (INCY) stock worth over $196 Million. Baker Biotech Capital (gp), Llc is also the Director, 10% Owner of Genomic Health Inc and owns about 1,484,977 shares of Genomic Health Inc (GHDX) stock worth over $94 Million. Besides these, Baker Biotech Capital (gp), Llc also holds BioCryst Pharmaceuticals Inc (BCRX) . Details can be seen in Baker Biotech Capital (gp), Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Baker Biotech Capital (gp), Llc has not made any transactions after 2012-03-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Baker Biotech Capital (gp), Llc

Baker Biotech Capital (gp), Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Baker Biotech Capital (gp), Llc owns 8 companies in total, including Ocera Therapeutics Inc (OCRX) , XOMA Royalty Corp (XOMA) , and Seagen Inc (SGEN) among others .

Click here to see the complete history of Baker Biotech Capital (gp), Llc’s form 4 insider trades.

Insider Ownership Summary of Baker Biotech Capital (gp), Llc

Ticker	Comapny	Transaction Date	Type of Owner
OCRX	Ocera Therapeutics Inc	2012-03-12	10 percent owner
XOMA	XOMA Royalty Corp	2012-03-06	10 percent owner
SGEN	Seagen Inc	2009-08-11	director & 10 percent owner
		2009-10-19	10 percent owner
		2010-09-23	director
		2007-08-06	10 percent owner
		2006-03-24	10 percent owner
		2012-03-06	10 percent owner

Baker Biotech Capital (gp), Llc Latest Holdings Summary

Baker Biotech Capital (gp), Llc currently owns a total of 4 stocks. Among these stocks, Baker Biotech Capital (gp), Llc owns 4,626,213 shares of Seagen Inc (SGEN) as of August 11, 2009, with a value of $1.1 Billion and a weighting of 77.7%. Baker Biotech Capital (gp), Llc owns 2,933,021 shares of Incyte Corp (INCY) as of September 23, 2010, with a value of $196 Million and a weighting of 14.4%. Baker Biotech Capital (gp), Llc also owns 1,484,977 shares of Genomic Health Inc (GHDX) as of March 8, 2012, with a value of $94 Million and a weighting of 6.92%. The other 1 stocks BioCryst Pharmaceuticals Inc (BCRX) have a combined weighting of 0.99% among all his current holdings.

Latest Holdings of Baker Biotech Capital (gp), Llc

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
SGEN	Seagen Inc	2009-08-11	4,626,213	228.74	1,058,199,962
INCY	Incyte Corp	2010-09-23	2,933,021	66.85	196,072,454
GHDX	Genomic Health Inc	2012-03-08	1,484,977	63.44	94,206,941
BCRX	BioCryst Pharmaceuticals Inc	2007-08-06	1,650,290	8.16	13,466,366

Holding Weightings of Baker Biotech Capital (gp), Llc

Baker Biotech Capital (gp), Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Baker Biotech Capital (gp), Llc has made a total of 0 transactions in Seagen Inc (SGEN) over the past 5 years. The most-recent trade in Seagen Inc is the acquisition of 273,404 shares on August 11, 2009, which cost Baker Biotech Capital (gp), Llc around $3 Million.

According to the SEC Form 4 filings, Baker Biotech Capital (gp), Llc has made a total of 0 transactions in Incyte Corp (INCY) over the past 5 years. The most-recent trade in Incyte Corp is the sale of 397,050 shares on September 23, 2010, which brought Baker Biotech Capital (gp), Llc around $6 Million.

According to the SEC Form 4 filings, Baker Biotech Capital (gp), Llc has made a total of 0 transactions in Genomic Health Inc (GHDX) over the past 5 years. The most-recent trade in Genomic Health Inc is the acquisition of 4,508 shares on March 8, 2012, which cost Baker Biotech Capital (gp), Llc around $135,736.

More details on Baker Biotech Capital (gp), Llc's insider transactions can be found in the Insider Trading History of Baker Biotech Capital (gp), Llc table.

Insider Trading History of Baker Biotech Capital (gp), Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Baker Biotech Capital (gp), Llc Trading Performance

GuruFocus tracks the stock performance after each of Baker Biotech Capital (gp), Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Baker Biotech Capital (gp), Llc is 11.76%. GuruFocus also compares Baker Biotech Capital (gp), Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Baker Biotech Capital (gp), Llc within 3 months outperforms 49 times out of 68 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Baker Biotech Capital (gp), Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Baker Biotech Capital (gp), Llc

Average Return

Average return per transaction

Outperforming Transactions

42 out of 68 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	5.03
Relative Return to S&P 500(%)	3.88

Baker Biotech Capital (gp), Llc Ownership Network

Ownership Network List of Baker Biotech Capital (gp), Llc

No Data

Ownership Network Relation of Baker Biotech Capital (gp), Llc

Baker Biotech Capital (gp), Llc Owned Company Details

What does Ocera Therapeutics Inc do?

Who are the key executives at Ocera Therapeutics Inc?

Baker Biotech Capital (gp), Llc is the 10 percent owner of Ocera Therapeutics Inc. Other key executives at Ocera Therapeutics Inc include 10 percent owner Brian H Dovey , 10 percent owner Domain Partners Viii, L.p. , and 10 percent owner Dp Viii Associates, L.p. .

Ocera Therapeutics Inc (OCRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ocera Therapeutics Inc (OCRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ocera Therapeutics Inc (OCRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ocera Therapeutics Inc (OCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ocera Therapeutics Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

Baker Biotech Capital (gp), Llc is the 10 percent owner of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , director & Interim CEO Owen Hughes , and other: See Explanation of Responses Biotechnology Value Fund L P .

XOMA Royalty Corp (XOMA) Insider Trades Summary

Over the past 18 months, Baker Biotech Capital (gp), Llc made no insider transaction in XOMA Royalty Corp (XOMA). Other recent insider transactions involving XOMA Royalty Corp (XOMA) include a net purchase of 9,100 shares made by Bradley Sitko , and a net purchase of 5,500 shares made by Owen Hughes .

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMA) were sold and 14,600 shares were bought by its insiders, resulting in a net purchase of 14,600 shares.

XOMA Royalty Corp (XOMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does Seagen Inc do?

Who are the key executives at Seagen Inc?

Baker Biotech Capital (gp), Llc is the director & 10 percent owner of Seagen Inc. Other key executives at Seagen Inc include director & Chief Executive Officer David R Epstein , See Remarks Vaughn B Himes , and EVP & Commercial Charles R Romp .

Seagen Inc (SGEN) Insider Trades Summary

Over the past 18 months, Baker Biotech Capital (gp), Llc made no insider transaction in Seagen Inc (SGEN). Other recent insider transactions involving Seagen Inc (SGEN) include a net sale of 36,274 shares made by Vaughn B Himes , a net sale of 2,228 shares made by Charles R Romp , and a net sale of 58,274 shares made by Todd E Simpson .

In summary, during the past 3 months, insiders sold 0 shares of Seagen Inc (SGEN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 195,202 shares of Seagen Inc (SGEN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 195,202 shares.

Seagen Inc (SGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Seagen Inc Insider Transactions

No Available Data

What does Heron Therapeutics Inc do?

Who are the key executives at Heron Therapeutics Inc?

Baker Biotech Capital (gp), Llc is the 10 percent owner of Heron Therapeutics Inc. Other key executives at Heron Therapeutics Inc include EVP & Chief Development Officer William P Forbes , other: See Footnote 2 Adam Morgan , and EVP & Chief Financial Officer Ira Duarte .

Heron Therapeutics Inc (HRTX) Insider Trades Summary

Over the past 18 months, Baker Biotech Capital (gp), Llc made no insider transaction in Heron Therapeutics Inc (HRTX). Other recent insider transactions involving Heron Therapeutics Inc (HRTX) include a net purchase of 2,486,744 shares made by Adam Morgan , and a net purchase of 50,000 shares made by William P Forbes .

In summary, during the past 3 months, insiders sold 0 shares of Heron Therapeutics Inc (HRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Heron Therapeutics Inc (HRTX) were sold and 2,536,744 shares were bought by its insiders, resulting in a net purchase of 2,536,744 shares.

Heron Therapeutics Inc (HRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Heron Therapeutics Inc Insider Transactions

No Available Data

What does Incyte Corp do?

Who are the key executives at Incyte Corp?

Baker Biotech Capital (gp), Llc is the director of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & General Manager & Europe Jonathan Elliott Dickinson , and EVP & Chief Medical Officer Steven H Stein .

Incyte Corp (INCY) Insider Trades Summary

Over the past 18 months, Baker Biotech Capital (gp), Llc made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net sale of 40,484 shares made by Steven H Stein , a net sale of 28,618 shares made by Barry P Flannelly , and a net sale of 3,324 shares made by Thomas Tray .

In summary, during the past 3 months, insiders sold 46,037 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 46,037 shares. During the past 18 months, 105,553 shares of Incyte Corp (INCY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 105,553 shares.

Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Incyte Corp Insider Transactions

No Available Data

What does BioCryst Pharmaceuticals Inc do?

Who are the key executives at BioCryst Pharmaceuticals Inc?

Baker Biotech Capital (gp), Llc is the 10 percent owner of BioCryst Pharmaceuticals Inc. Other key executives at BioCryst Pharmaceuticals Inc include Chief Financial Officer Anthony Doyle , Vice President and CCO Charles K Gayer , and VP & General Counsel & Corp Sec Alane P Barnes .

BioCryst Pharmaceuticals Inc (BCRX) Insider Trades Summary

Over the past 18 months, Baker Biotech Capital (gp), Llc made no insider transaction in BioCryst Pharmaceuticals Inc (BCRX). Other recent insider transactions involving BioCryst Pharmaceuticals Inc (BCRX) include a net purchase of 23,000 shares made by Helen M. Thackray , a net sale of 8,689 shares made by Machelle Sanders , and a net sale of 7,866 shares made by Nancy J Hutson .

In summary, during the past 3 months, insiders sold 8,600 shares of BioCryst Pharmaceuticals Inc (BCRX) in total and bought 0 shares, with a net sale of 8,600 shares. During the past 18 months, 43,853 shares of BioCryst Pharmaceuticals Inc (BCRX) were sold and 183,601 shares were bought by its insiders, resulting in a net purchase of 139,748 shares.

BioCryst Pharmaceuticals Inc (BCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioCryst Pharmaceuticals Inc Insider Transactions

No Available Data

What does Aceragen Inc do?

Who are the key executives at Aceragen Inc?

Baker Biotech Capital (gp), Llc is the 10 percent owner of Aceragen Inc. Other key executives at Aceragen Inc include director & President & CEO Vincent Milano , director & 10 percent owner Pillar Invest Corp , and 10 percent owner Atul Chopra .

Aceragen Inc (ACGN) Insider Trades Summary

Over the past 18 months, Baker Biotech Capital (gp), Llc made no insider transaction in Aceragen Inc (ACGN). Other recent insider transactions involving Aceragen Inc (ACGN) include a net sale of 264,324 shares made by Atul Chopra , a net purchase of 21,147 shares made by Pillar Invest Corp , and a net sale of 3,283 shares made by Vincent Milano .

In summary, during the past 3 months, insiders sold 0 shares of Aceragen Inc (ACGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 273,476 shares of Aceragen Inc (ACGN) were sold and 26,965 shares were bought by its insiders, resulting in a net sale of 246,511 shares.

Aceragen Inc (ACGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aceragen Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

XOMA Royalty Corp (XOMAO.PFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMAO.PFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMAO.PFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

XOMA Royalty Corp (XOMAO.PFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

Baker Biotech Capital (gp), Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Baker Biotech Capital (gp), Llc. You might contact Baker Biotech Capital (gp), Llc via mailing address: 667 Madison Ave, 21st Floor,, New York Ny 10065.

Discussions on Baker Biotech Capital (gp), Llc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.